Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Literature DB >> 11897598

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Lisa Saiman¹, Yunhua Chen, Pablo San Gabriel, Charles Knirsch.

Abstract

Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 11897598 PMCID： PMC127106 DOI： 10.1128/AAC.46.4.1105-1107.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

23 in total

1. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

Authors: R L Henry; C M Mellis; L Petrovic
Journal: Pediatr Pulmonol Date: 1992-03

Review 2. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan.

Authors: H Tanimoto
Journal: Antibiot Chemother (1971) Date: 1991

3. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides.

Authors: H Kobayashi
Journal: Am J Med Date: 1995-12-29 Impact factor: 4.965

Review 4. Diffuse panbronchiolitis.

Authors: Y Sugiyama
Journal: Clin Chest Med Date: 1993-12 Impact factor: 2.878

Review 5. Microbiology of airway disease in patients with cystic fibrosis.

Authors: P H Gilligan
Journal: Clin Microbiol Rev Date: 1991-01 Impact factor: 26.132

6. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

Authors: G Molinari; C A Guzmán; A Pesce; G C Schito
Journal: J Antimicrob Chemother Date: 1993-05 Impact factor: 5.790

7. The changing epidemiology of cystic fibrosis.

Authors: S C FitzSimmons
Journal: J Pediatr Date: 1993-01 Impact factor: 4.406

8. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation.

Authors: T Ichimiya; T Yamasaki; M Nasu
Journal: J Antimicrob Chemother Date: 1994-09 Impact factor: 5.790

9. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin.

Authors: M J Dupont; J R Lapointe
Journal: J Antimicrob Chemother Date: 1995-07 Impact factor: 5.790

10. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.

Authors: R Mizukane; Y Hirakata; M Kaku; Y Ishii; N Furuya; K Ishida; H Koga; S Kohno; K Yamaguchi
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.938

27 in total

1. Cloning, overexpression, and characterization of a novel thermostable penicillin G acylase from Achromobacter xylosoxidans: probing the molecular basis for its high thermostability.

Authors: Gang Cai; Songcheng Zhu; Sheng Yang; Guoping Zhao; Weihong Jiang
Journal: Appl Environ Microbiol Date: 2004-05 Impact factor: 4.792

Review 2. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors: Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal: Expert Rev Anti Infect Ther Date: 2018-01-16 Impact factor: 5.091

3. Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors: Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

4. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Authors: Dominic Hill; Barbara Rose; Aniko Pajkos; Michael Robinson; Peter Bye; Scott Bell; Mark Elkins; Barbara Thompson; Colin Macleod; Shawn D Aaron; Colin Harbour
Journal: J Clin Microbiol Date: 2005-10 Impact factor: 5.948

Review 5. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors: Souha S Kanj; Zeina A Kanafani
Journal: Mayo Clin Proc Date: 2011-03 Impact factor: 7.616

6. Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Authors: Zackery P Bulman; Neang S Ly; Justin R Lenhard; Patricia N Holden; Jürgen B Bulitta; Brian T Tsuji
Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191

Review 7. Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors: Axel Dalhoff
Journal: Clin Microbiol Rev Date: 2014-10 Impact factor: 26.132